Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Viridian Therapeutics reported positive topline data from elegrobart's phase 3 clinical trials for thyroid eye disease (TED) and is preparing to launch veligrotug with a PDUFA target date of June 30, 2026. The company has completed hiring its field team and established commercial supply and manufacturing infrastructure.
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company, reported recent business highlights and financial results for the first quarter ended March 31, 2026. The company's veligrotug BLA is under Priority Review at the FDA with a PDUFA target action date of June 30, 2026. Veligrotug received Breakthrough Therapy Designation and Priority Review from the FDA in 2025. Viridian has completed hiring its field team and established commercial supply and manufacturing infrastructure. The company announced positive topline data from elegrobart's two pivotal phase 3 clinical trials for TED. Elegrobart met its primary endpoint in both trials, showing rapid onset of treatment effect and clinically meaningful improvements. Viridian plans to submit a BLA to the FDA in Q1 2027 and launch elegrobart as the first simple and convenient autoinjector for TED patients.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.